Inclusion of information related to: | ||
---|---|---|
1. Available evidence primary CVD prevention for older people | 2. Barriers to implementation of the CPG for older people | 3. Tailoring treatment to older people context and preferences |
a. Evidence potential benefits/harms | a. Risk assessment complexity (e.g. measurement issues) | a. Patient preferences/values |
b. Knowledge gaps | b. Risk management complexity (e.g. feasibility treatment targets) | b. Family preferences/values |
 | c. Time needed to treat to benefit in context of life expectancy | c. Patient context (e.g. quality of life, life expectancy, comorbidities) |
 | d. Meaningfulness outcomes for older people | d. Weighing benefits/harms |
 | e. Treatment adherence issues | e. Therapy prioritization |
 | f. Cognitive status |  |
 | g. Social support/caregiver burden |  |